Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress

Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will join Avidity management to present data from FORTITUDE™ Avidity to host Volume 9 of investor and analyst event series via webcast June 12, 2024, at 8:00 a.m. ET…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks